TICKERNERD
Menu
ILMNILMNHealthcare · Diagnostics & Research

ILMN Stock Forecast: Illumina, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$205
−2.87% on the day

The 20 Wall Street analysts covering Illumina, Inc. hold a median 12-month price target of $213 — +3.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 8 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$33.0B
Ticker Nerd rank
95 / 100
Median analyst target
$213
Analysts covering
20
Revenue$1.1B+4.8% y/y
Operating income$209.0M
Net income$134.0M
Free cash flow$251.0M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.0%
1M
+9.1%
YTD
+56.3%
1Y
+108.7%
From 52W high
−10.0%
From 52W low
+125.3%
$91
$228
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ILMN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Illumina, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
95 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Momentum
96
Revisions
91
Issuance
91
Value
87
Volatility
76
Accruals
45
Growth
43
Size
7

Quality (98): The business earns solid, repeatable profits on what it owns.

Growth (43): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ILMN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ILMN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$150$200Oct 25Jan 26Apr 26Jul 26ILMNHigh $230Median $213Low $113

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
10 Buy6 Hold4 Sell
Low $113Median $213High $230

The green dot is the last close — the median target sits +3.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Sept 2026Argus ResearchMaintainsBuy$180 → $235
3 Aug 2026Canaccord GenuityMaintainsHold—
3 Aug 2026Canaccord GenuityMaintainsHold$190 → $205
3 Aug 2026CitigroupMaintainsSell$95 → $113
3 Aug 2026CitigroupMaintainsSell—
3 Aug 2026Piper SandlerReiteratesOverweight—
3 Aug 2026Piper SandlerReiteratesOverweight$200 → $225
31 July 2026BarclaysMaintainsUnderweight$145 → $160
31 July 2026BarclaysMaintainsUnderweight—
31 July 2026GuggenheimMaintainsBuy$200 → $226
31 July 2026GuggenheimMaintainsBuy—
31 July 2026JP MorganMaintainsOverweight$220 → $230
31 July 2026JP MorganMaintainsOverweight—
31 July 2026RBC CapitalMaintainsOutperform$170 → $230
31 July 2026RBC CapitalMaintainsOutperform—
31 July 2026StifelMaintainsBuy—
31 July 2026StifelMaintainsBuy$155 → $225
31 July 2026TD CowenMaintainsHold$192 → $210
31 July 2026TD CowenMaintainsHold—
17 July 2026Leerink PartnersMaintainsOutperform$175 → $210

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ILMN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ILMN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Illumina, Inc. returned +108.7% against +18.5% for the S&P 500, dividends included.

ILMN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26ILMNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ILMN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.5%
Analysts raising
16
Analysts cutting
0
Fundamentals

Illumina, Inc. (ILMN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
39.9×

Cheaper than 19% of US stocks

Price / sales
7.2×

Cheaper than 18% of US stocks

Price / book
11.4×

Cheaper than 8% of US stocks

EV / EBITDA
29.7×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
9.4%

Higher than 50% of US stocks

Earnings growth (YoY)
−11.9%

Higher than 25% of US stocks

Gross margin
66.1%

Higher than 80% of US stocks

Operating margin
21.1%

Higher than 80% of US stocks

Net margin
18.3%

Higher than 81% of US stocks

Returns & dividend
Return on equity
32.3%

Higher than 89% of US stocks

Return on assets
8.7%

Higher than 90% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Illumina, Inc. (ILMN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Illumina, Inc. has a market value of $33.0B and an enterprise value of $34.3B.

  • Revenue in the twelve months to 31 Mar 2026: $4.4B. The latest quarter grew 9.4% year on year.

  • Net income over the same four quarters: $853.0M, a 19.4% net margin.

  • Diluted earnings per share, trailing twelve months: $5.50.

  • Free cash flow in the twelve months to 31 Mar 2026: $967.0M, after $154.0M of capital spending.

  • Illumina, Inc. spent $784.0M on share buybacks in the twelve months to 31 Mar 2026.

  • Shares outstanding: 151.0M.

  • Trailing P/E: 39.9×; forward P/E: 35.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Illumina, Inc. employs 8,600 people — $511K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 10 Sept 2026

Data provided by Twelve Data

Peers

ILMN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
ILMNIllumina, Inc.$33.0B
95
MTDMettler-Toledo International, Inc.$27.1B
91
LHLabcorp Holdings, Inc.$26.9B
86
DGXQuest Diagnostics, Inc.$26.2B
94
WATWaters Corp.$39.5B
52
IDXXIDEXX Laboratories, Inc.$41.5B
92
AAgilent Technologies, Inc.$41.6B
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Illumina, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ILMN news & analysis

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Benzinga · 9 Sept 2026positive

Benzinga reported that a Wall Street analyst turned bullish on Illumina, with the company listed among the top five analyst upgrades for Wednesday. The item notes that analysts changed their outlook on these top names, and directs readers to a full ratings page for more detail.

Why it matters — An analyst upgrade to a bullish stance is a notable shift in sentiment that ILMN watchers would want to track for its potential impact on view of the stock.

3 Stocks Soon Joining the S&P 500

Zacks Investment Research · 9 Sept 2026positive

The S&P 500 is set for a quarterly rebalancing near the end of September, with Illumina (ILMN) among three stocks joining the index, along with Bloom Energy (BE) and Everpure (P).

Why it matters — An ILMN watcher would care because inclusion in the S&P 500 typically brings broader index-fund demand and increased investor visibility for the company.

3 Promising Genomics Stocks in the Spotlight in 2026

Zacks Investment Research · 8 Sept 2026neutral

A Zacks Investment Research piece spotlights three promising genomics stocks — WGS, NEO and NTLA — for 2026, noting how genomics is reshaping healthcare by advancing diagnostics and precision medicine. Illumina is not directly mentioned in the article.

Why it matters — The item signals broader momentum in the genomics sector, which could be relevant context for Illumina watchers even though ILMN is not covered in the piece.

Illumina (ILMN) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 7 Sept 2026positive

Illumina (ILMN) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade could potentially drive the stock higher in the near term.

Why it matters — An upgrade to a Zacks Rank #2 (Buy) signals increased confidence in Illumina's earnings outlook, which an ILMN watcher would care about as it indicates a more favorable assessment of the company's prospects.

Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

PRNewsWire · 4 Sept 2026positive

S&P Dow Jones Indices announced that Illumina, along with Bloom Energy and Everpure, will join the S&P 500 as part of the quarterly rebalance, effective prior to the open of trading on Monday, September 21, 2026. Other companies are also being added to the S&P 100, S&P MidCap 400, and S&P SmallCap 600.

Why it matters — Inclusion in the S&P 500 is a significant index change that typically increases a stock's visibility and can affect demand among index-tracking funds.

FAQ

Frequently asked questions about ILMN stock

What is the ILMN stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Illumina, Inc. have a median 12-month price target of $213, with estimates ranging from $113 to $230. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ILMN stock a buy right now?

Of the 20 analysts covering Illumina, Inc., 10 rate it a Buy, 6 a Hold and 4 a Sell. Ticker Nerd's systematic factor model ranks Illumina, Inc. 95 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ILMN?

As at 8 Sept 2026, Illumina, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will ILMN stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +3.9% from the last close, and Ticker Nerd's factor model ranks Illumina, Inc. 95 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ILMN stock forecast for 2030?

No analyst covering Illumina, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ILMN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $113 to $230 over the next 12 months.

How has ILMN stock performed over the past year?

Illumina, Inc. returned +108.7% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Illumina, Inc. do?

Illumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function.

What is the latest news on ILMN?

The most recent item we track (Benzinga, 9 Sept 2026): "This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday". Benzinga reported that a Wall Street analyst turned bullish on Illumina, with the company listed among the top five analyst upgrades for Wednesday. The item notes that analysts changed their outlook on these top names, and directs readers to a full ratings page for more detail.

Company

About Illumina, Inc.

Illumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function. Its products and systems support research, clinical testing, and applied markets across areas such as oncology, inherited and infectious diseases, reproductive health, and molecular diagnostics. Illumina also provides sequencing consumables, instruments, software, and support services that help laboratories generate, interpret, and manage genomic data. The company serves customers including academic institutions, genomic research centers, hospitals, pharmaceutical and biotechnology companies, and clinical laboratories. Headquartered in San Diego, California, and founded in 1998, Illumina plays a central role in making genomic analysis more widely accessible for research and healthcare applications.

CEO Mr. Jacob Thaysen Ph.D. · 8,600 employees · United States · https://www.illumina.com